A carregar...
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer
SIMPLE SUMMARY: The anti-PD1 monoclonal antibody pembrolizumab improves survival in recurrent/metastatic head and neck squamous cell carcinoma. Patients with locoregional, pathologically high-risk disease recur frequently despite adjuvant cisplatin–radiation therapy. Targeting PD1 may reverse immuno...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8230356/ https://ncbi.nlm.nih.gov/pubmed/34207599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13122882 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|